---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-072851"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:56:07.467453+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics Q3 net loss of $5M; cash at $3.9M; substantial doubt about going concern

## Summary
- Cash $3.9M as of Sept 30, 2022, down from $19.6M at Dec 31, 2021.
- Net loss of $5.0M in Q3 2022 vs $1.4M in Q3 2021; R&D expense rose to $3.0M.
- Cash insufficient to fund operations beyond Dec 31, 2022; going concern warning issued.
- In discussions with Series A preferred holder for bridge loan; no assurance of success.

## SEC filing metadata
- accession: 0001213900-22-072851
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/0001213900-22-072851-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/ea168752-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-072851
- JSON: https://secwatch.observer/filing/0001213900-22-072851.json
- Plain text: https://secwatch.observer/filing/0001213900-22-072851.txt

## Key facts
- Earnings Releases
  Allarity Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $5.0 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $5.0 million
  - Result: reported results
  source text: Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/0001213900-22-072851-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.